47-P | A survey of regional anaesthetic practice in immune and gestational thrombocytopenia in pregnancy | Marwa Salman | Received |
49-P | Audit of the use of chest X-rays in the management of adult neutropenic sepsis at Kings College Hospital, London | CY Zhu | Received |
51-P | Anticoagulation in patients undergoing cardioversion at Hampshire Hospitals NHS Foundation Trust | Sufyan Benamer | Received |
52-P | A study of the implementation of romiplostim & eltrombopag in the NHS in England | Lisa Cooper | Received |
53-P | Evaluation of the body fluid mode on the XE-5000 for counting leukocytes in bronchoalveolar lavage fluid | Lucie Gruchalova | Received |
55-P | The impact of formal chemotherapy training on haematology registrars | Joanna Collins | Received |
56-P | Formalising palliative care education augments clinical skills in haematology trainees | Rosanna Ghinai | Received |
58-P | Idiopathic systemic capillary leak syndrome treated successfully with maintenance intravenous immunoglobulin | Andrew King | Received |
59-P | Management of the Choose and Book system for polycythaemia/thrombocytosis by the MPN specialist nurse | Louise Wallis | Received |
61-P | The development and review of performance assessment scoring in blood films for parasites external quality assessment | Paul McTaggart | Received |
62-P | Second line treatment for immune thrombocytopenia (ITP): A review of patients with ITP in Basildon Hospital | Katie White | Received |
72-P | New conclusions in scintigraphy results of sickle cell disease bone involvements | Hasan Al-Jafar | Received |
76-P | Annual British Society for Haematology confidential survey of bone marrow examination associated adverse events 2013 | Vinod Devalia | Received |
81-P | The use of thrombopoeitin (TPO) as a Biomarker in Immune Thrombocytopenia (ITP) | George Adams | Received |
82-P | The effects of Triton-X on haematological assays when used as an inactivator for Ebola virus | Alexander Gatt | Received |
83-P | A case report may lead to addendum to BSH treatment guideline of acquired VWD | Hassan Al-Jafar | Received |
87-P | Recurrence of VTE over four years: Local outcome data to determine and compare location of VTE events for hospital or community acquired VTE | Huw Rowswell | Received |
88-P | Direct oral anti-coagulants for prevention of stroke and systemic embolism in non-valvular atrial fibrillation Barts Health experience across two sites | Pallavi Kalkur | Received |
90-P | A double-centre retrospective study into rates of postpartum haemorrhage in women on low molecular weight heparin | Rachel Browne | Received |
91-P | Acute nurse-led VTE service reduces admission and facilitates NOAC use for VTE | Marianna Koperdanova | Received |
93-P | Audit of the effect of the introduction of a guideline for the management of superficial vein thrombosis to a nurse-led DVT clinic | Charlotte Grimley | Received |
94-P | Evaluation of pathology quality assurance review recommendations: Data from a UK NEQAS for Blood Coagulation (UK NEQAS BC) questionnaire | Shelene Munroe-Peart | Received |
99-P | Review of factor XI deficiency: Bleeding phenotype and clnical considerations | Philip George | Received |
103-P | Cancer-associated VTE occurring over one year in a small district general hospital | Emma Harris | Received |
104-P | Patients with suspected TTP should be acutely managed in a critical care setting | Jennifer Burgess | Received |
108-P | Thrombopoietin-receptor agonists in immune thrombocytopaenic purpura: Our experience at East Kent Hospitals University NHS Foundation Trust | Kate Fletcher | Received |
120-P | Burden of venothromboembolism and thromboprophylaxis at East Kent Hospitals NHS Foundation Trust in patients with myeloma treated with immunomodulatory drugs (IMid) containing regimens between 2009 and 2014: A retrospective study | Catherine Roughley | Received |
121-P | Prospective audit of rivaroxaban as thromboprophylaxis and treatment during myeloma therapy with immunomodulatory drugs (IMiDs) at East Kent Hospitals NHS Foundation Trust | Catherine Roughley | Received |
123-P | MGUS Tracker an alternative way of monitoring MGUS outside the haematology clinic | Heather Eve | Received |
127-P | An audit of compliance with the NICE guideline for the use of lenalidomide therapy in patients with myeloma | ANANDIKA LIYANAGE | Received |
128-P | Significant gender differences in the number and distribution of T cells in patients with mantle cell lymphoma | Nimish Shah | Received |
132-P | Rare, fulminant presentations of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma a case series | Xiao-Yin Zhang | Received |
134-P | Outcomes from a single centre for patients with multiply relapsed myeloma treated with bendamustine containing regimens | Noel Ryman | Received |
139-P | Audit of central nervous system (CNS) prophylaxis in patient with diffuse large B-cell lymphoma (DLBCL) | Abdul Baseer Qadri | Received |
142-P | Life-threatening bowel perforation while on thalidomide-based triplet regimen for multiple myeloma: A retrospective case series | Priya Sriskandarajah | Received |
148-P | Off trial use of brentuximab vedotin in Hodgkin lymphoma a regional experience | Joseph Browning | Received |
156-P | Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience | Priya Sriskandarajah | Received |
165-P | Real world efficacy of pomalidomide for relapsed myeloma - a multicentre restrospective study | Matthew Wells | Received |
181-P | Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 micrometre tissue are required | Omar Alishlash | Received |
187-P | Efficacy of azacitidine in the treatment of acute myeloid leukaemia (blasts 30) in comparison to MDS | John Gaffney | Received |
188-P | Investigating differences in serum and plasma values in galactomannan testing, signal loss and sources of false positivity | Naeem Desai | Received |
191-P | Frequency and management of breakthrough fungal infections in patients with acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) on antifungal prophylaxis | Claire Burney | Received |
193-P | Single centre experience in the use of pegylated interferon alpha for myeloproliferative neoplasms | Meghna Ruparelia | Received |
199-P | Convenient care for patients: A real world evaluation to describe the NHS impact of administering velcade R (bortezomib) in a home setting for patients with multiple myeloma | Samantha Oliver | Received |
201-P | Alternate day lenalidomide as a well-tolerated and cost-effective treatment in multiple myeloma | Yeong Jer Lim | Received |
204-P | CALR mutations in myeloproliferative neoplasm related splanchnic vein thrombosis | Mallika Sekhar | Received |
206-P | How well are patients with myeloproliferative neoplasms assessed for cardiovascular risk: An audit report | Mallika Sekhar | Received |
220-P | Seroprevalence of undiagnosed transfusion transmissible infections (HIV, hepatitis B and C and syphilis) in donated blood in National Blood Banks, Khartoum, Sudan | doaa yousif | Received |
224-P | The impact of maternal allo-antibodies on the clinical outcomes of foetuses/neonates at Barts Health NHS Trust | Jessica Jardim | Received |
226-P | Incidence of Rh and Kell blood group antigens among blood donors in Qatar | Ibrahim Mustafa | Received |
227-P | Consent to long-term multiple blood transfusions for patients admitted to the haematology ward: A complete audit cycle and quality improvement project | Helen Perera | Received |
230-P | Successful renal transplantation in Jehovahs Witnesses shouldnt we apply our approach to blood refusers to all patients, to reduce risks associated with blood transfusions? | Charlotte Phillips | Received |
231-P | Contribution of the British Bone Marrow Registry (BBMR) to the UK transplant activity in 2007 and investigation of final donors in this year | Yousif Aawsaj | Received |
232-P | The use and outcomes of prothrombin complex concentrate in a district general hospital | julie blundell | Received |
238-P | High recruitment into interventional clinical trials is possible in the setting of a district general trust (DGT): Results of a short prospective audit | LAVINIA DAVEY | Received |
255-P | Haemoglobinopathy screening pathways and attitudes to opportunistic screening for haemoglobinopathies | Meghna Ruparelia | Received |
257-P | Safety and efficacy of elective automated red cell exchange transfusion programmes for patients with sickle cell disease | Paul Miller | Received |
20-22 April 2015 Edinburgh
COLLECT YOUR PRINTED POSTER ON-SITE AT THE REGISTRATION DESK |
---|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|